Companies › Acerta Pharma
6 active drug programs in 75 registered trials: 48 Phase 2, 15 Phase 1, 12 Phase 3; Oncology, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Acalabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Lymphoma, Mantle Cell; Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma (MCL) … | Dec 2026 |
| Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Diffuse Large B-Cell Lymphoma | Feb 2027 |
| Obinutuzumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 3 | Chronic Lymphocytic Leukemia | Apr 2027 |
| Chlorambucil Alkylating agent | – | Phase 3 | Chronic Lymphocytic Leukemia; MALT Lymphoma | – |
| ACP-319 Mechanism unclear | – | Phase 1 | Chronic Lymphocytic Leukemia | – |
| Ceralasertib (AZD6738) Serine-protein kinase ATR inhibitor | ATR | Phase 1 | Chronic Lymphocytic Leukemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02475681 | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Feb 2019 |
| NCT02475681 | Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Feb 2019 |
| NCT02475681 | Chlorambucil | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Feb 2019 |
| NCT02586857 | Acalabrutinib | Phase 1 | Glioblastoma Multiforme | Oncology | Jun 2020 |
| NCT02157324 | Acalabrutinib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Jul 2020 |
| NCT02157324 | ACP-319 | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Jul 2020 |
| NCT02717611 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Oct 2020 |
| NCT02213926 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma (MCL) | Oncology | Dec 2020 |
| NCT03328273 | Acalabrutinib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Sep 2021 |
| NCT03328273 | Ceralasertib (AZD6738) | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Sep 2021 |
| NCT05336812 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Oct 2026 |
| NCT05065554 | Acalabrutinib | Phase 2 | IgM MGUS | Neurology | Dec 2026 |
| NCT02180724 | Acalabrutinib | Phase 2 | Waldenström Macroglobulinemia (WM) | Oncology | Dec 2026 |
| NCT06757647 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Dec 2026 |
| NCT04115631 | Acalabrutinib | Phase 2 | Liver Lymphoma | Oncology | Dec 2026 |
| NCT04462328 | Acalabrutinib | Phase 1 | Primary Central Nervous System Lymphoma | Oncology | Dec 2026 |
| NCT05971251 | Acalabrutinib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT05943496 | Acalabrutinib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Jan 2027 |
| NCT05214183 | Acalabrutinib | Phase 2 | MCL | Oncology | Jan 2027 |
| NCT04883437 | Acalabrutinib | Phase 2 | Grade 1 Follicular Lymphoma | Oncology | Jan 2027 |
| NCT04978584 | Acalabrutinib | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Jan 2027 |
| NCT05256641 | Acalabrutinib | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Jan 2027 |
| NCT04906902 | Acalabrutinib | Phase 1 | Central Nervous System Lymphoma | Oncology | Jan 2027 |
| NCT04657094 | Acalabrutinib | Phase 2 | Autoimmune Hemolytic Anemia | Oncology | Feb 2027 |
| NCT02972840 | Acalabrutinib | Phase 3 | Lymphoma, Mantle Cell | Oncology | Feb 2027 |
| NCT04722172 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Feb 2027 |
| NCT04529772 | Acalabrutinib | Phase 3 | Diffuse Large B-Cell Lymphoma | Oncology | Feb 2027 |
| NCT04529772 | Rituximab | Phase 3 | Diffuse Large B-Cell Lymphoma | Oncology | Feb 2027 |
| NCT04484012 | Acalabrutinib | Phase 2 | Recurrent Mantle Cell Lymphoma | Oncology | Feb 2027 |
| NCT03836261 | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Apr 2027 |
| NCT04198922 | Acalabrutinib | Phase 2 | Recurrent Moderate-Severe Chronic Graft Versus Host Disease | Oncology | Apr 2027 |
| NCT03836261 | Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Apr 2027 |
| NCT04002947 | Acalabrutinib | Phase 2 | Non-Hodgkin's Lymphoma | Oncology | May 2027 |
| NCT02029443 | Acalabrutinib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Jun 2027 |
| NCT04189757 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Jun 2027 |
| NCT04505254 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Jun 2027 |
| NCT04855695 | Acalabrutinib | Phase 1 | Mantle Cell Lymphoma | Oncology | Jun 2027 |
| NCT06054776 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Jul 2027 |
| NCT04783415 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Jul 2027 |
| NCT04941716 | Acalabrutinib | Phase 2 | Recurrent Chronic Lymphocytic Leukemia | Oncology | Aug 2027 |
| NCT02717624 | Acalabrutinib | Phase 1 | Mantle Cell Lymphoma (MCL) | Oncology | Aug 2027 |
| NCT04646395 | Acalabrutinib | Phase 2 | Marginal Zone Lymphoma | Oncology | Sep 2027 |
| NCT02970318 | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Oct 2027 |
| NCT04546620 | Acalabrutinib | Phase 2 | Diffuse Large B Cell Lymphoma | Oncology | Nov 2027 |
| NCT03580928 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | Oncology | Dec 2027 |
| NCT04624633 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Jan 2028 |
| NCT02477696 | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | Jan 2028 |
| NCT03946878 | Acalabrutinib | Phase 2 | Blastoid Variant Mantle Cell Lymphoma | Oncology | Feb 2028 |
| NCT04560322 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Mar 2028 |
| NCT04404088 | Acalabrutinib | Phase 2 | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Oncology | Mar 2028 |
| NCT05197192 | Acalabrutinib | Phase 3 | Chronic Lymphocytic Leukemia | Oncology | May 2028 |
| NCT03863184 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | May 2028 |
| NCT07014917 | Acalabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Jun 2028 |
| NCT05004064 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Jun 2028 |
| NCT03899337 | Acalabrutinib | Phase 2 | Richter Syndrome | Oncology | Jun 2028 |
| NCT04169737 | Acalabrutinib | Phase 2 | Recurrent Chronic Lymphocytic Leukemia | Oncology | Jul 2028 |
| NCT04963946 | Acalabrutinib | Phase 2 | Untreated Chronic Lymphocytic Leukemia | Oncology | Aug 2028 |
| NCT04626791 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Aug 2028 |
| NCT04765111 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Aug 2028 |
| NCT04566887 | Acalabrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Sep 2028 |
The 60 nearest readouts of 75 trials; the rest in the app.
Roche AstraZeneca Biocad Novartis Sanofi BeOne Medicines Eli Lilly Regeneron Pharmaceuticals Sandoz Celltrion
Lepu Biopharma R-Pharm GC Cell Genfleet Therapeutics (Shanghai) Immunocore
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.